Moody National Bank Trust Division Acquires Shares of 10,427 Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Moody National Bank Trust Division acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE: ZBH), purchasing 10,427 shares valued at approximately $951,000.
• Several institutional investors increased their positions in Zimmer Biomet, with notable changes from Ameriprise Financial and JPMorgan Chase, indicating strong interest in the firm.
• ZBH recently reported earnings per share (EPS) of $2.07 for the quarter, surpassing analysts' expectations and demonstrating a 7.0% increase in revenue year-over-year.

Moody National Bank Trust Division bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 10,427 shares of the medical equipment provider's stock, valued at approximately $951,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ZBH. Ameriprise Financial Inc. boosted its position in shares of Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock worth $517,039,000 after buying an additional 3,208,596 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Zimmer Biomet by 251.3% during the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after buying an additional 1,488,918 shares during the period. Nuveen LLC acquired a new position in shares of Zimmer Biomet during the first quarter worth approximately $155,891,000. Alyeska Investment Group L.P. acquired a new position in shares of Zimmer Biomet during the first quarter worth approximately $101,294,000. Finally, Boston Trust Walden Corp acquired a new position in shares of Zimmer Biomet during the first quarter worth approximately $54,108,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 1.8%

Zimmer Biomet stock traded up $1.78 during mid-day trading on Monday, hitting $101.87. 766,935 shares of the company's stock were exchanged, compared to its average volume of 1,979,419. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The stock has a market cap of $20.18 billion, a P/E ratio of 24.75, a P/E/G ratio of 2.30 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The stock has a 50 day moving average of $100.06 and a two-hundred day moving average of $99.35.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. During the same period in the prior year, the company earned $2.01 earnings per share. The business's quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet's dividend payout ratio (DPR) is currently 23.36%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ZBH. Stifel Nicolaus boosted their price objective on Zimmer Biomet from $115.00 to $118.00 and gave the stock a "buy" rating in a research report on Friday. Redburn Partners set a $130.00 target price on Zimmer Biomet in a research report on Thursday. Raymond James Financial upped their target price on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Rothschild Redb upgraded Zimmer Biomet to a "strong-buy" rating in a research report on Thursday. Finally, Evercore ISI cut their target price on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $113.16.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares of the company's stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.70% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.